Gilead Sciences Aktie News

Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.

Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On October 23, Gilead announced that it will announce data on the switching of people with PBC from obeticholic acid to its 'rising star' Livdelzi at The Liver Meeting 2025.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and v...

WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's leadership in advancing a...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative brea...

Gilead Sciences (GILD) is a top-performing healthcare stock in 2025, up 36% YTD and breaking out to all-time highs. GILD's strong Q2 results, raised guidance, and robust HIV portfolio drive optimism, with FDA approval and delayed Biktarvy exclusivity boosting long-term prospects. Valuation remains attractive, with technical analysis signaling potential upside to $150 in the near term and $185 l...